Mark is the Chief Technology Officer and one of the founding scientists of Volition. He is an enthusiastic and passionate biotechnology entrepreneur with over 25 years’ experience in the sector. He is focused not only on identifying new and innovative technology platforms, but also on ensuring they are fit for purpose now and in the future, all of which will aid the deployment of Volition’s proprietary Nu.Q™ platform
Mark is also the Managing Director of OncoLytika Ltd. a technical consultancy company working with international private and public limited companies operating in the diagnostics and therapeutic sectors as well as academia.
Mark received a PhD in Polymer Chemistry for biomedical applications and an MBA (entrepreneurship) from the University of Dundee in 2008.
" It is tremendously rewarding working on such a cutting-edge technology – one that has the potential to not only help diagnose cancer, but also potentially many other conditions."